Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110217 | 0.86 | ALDH1A1 (0.44) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL14207831 | 0.86 | ALDH1A1 (0.44) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL7045810 | 0.84 | ALDH1A1 (0.43) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL14207825 | 0.82 | NPC1 (0.56) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL14207816 | 0.81 | SMN1; SMN2 (0.39) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL21617021 | 0.80 | POLB (0.43) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL25923625 | 0.77 | L3MBTL1 (0.50) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2134732 | 0.75 | ALDH1A1 (0.57) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL1145938 | 0.74 | ALDH1A1 (0.54) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL23355979 | 0.74 | ALDH1A1 (0.42) | NPC1RAB9APOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919627-B2 | Synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine derivatives by protecting the hydroxyl group of (6-chloro-pyridin-3-yl)-methanol, reacting with pyrazole, and reacting with hydroxylamine or a derivative or an oxime | ENANTA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919627-B2 | Synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine derivatives by protecting the hydroxyl group of (6-chloro-pyridin-3-yl)-methanol, reacting with pyrazole, and reacting with hydroxylamine or a derivative or an oxime | ENANTA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7538225-B2 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538225-B2 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | TANG DATONG | 2008-10-02 | — | — | US | disclosed |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | TANG DATONG | 2008-10-02 | — | — | US | disclosed |
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | SHIONOGI & CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | SHIONOGI & CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | SHIONOGI & CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1829870-A1 | 2-(PYRAZOL-1-YL)PYRIDINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829870-A1 | 2-(PYRAZOL-1-YL)PYRIDINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086007-A1 | 2-(Pyrazole-1-Yl)Pyridine Derivative | MRPL21, CYP1A2, PDXK | NPC1 4279/4885RAB9A 1444/4885POLB 2943/4885 |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | CYP2B6, CYP2D6, CYP3A5 | NPC1 2717/4885RAB9A 3524/4885POLB 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.